Skip to main content

Table 9 Proportions of resistance to second-line injectable drugs and streptomycin stratified by age groups

From: Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study

 15–3435–59≥60Totalp-value
Non-multidrug-resistance TB692 (100.0%)1512 (100.0%)2034 (100.0%)4238 (100.0%) 
 Resistance to any SLIDa2 (0.3%)2 (0.1%)12 (0.6%)16 (0.4%)0.082
 Km resistance0 (0.0%)1 (0.1%)6 (0.3%)7 (0.2%)0.127
 Am resistance0 (0.0%)1 (0.1%)5 (0.2%)6 (0.1%)0.207
 Cm resistance2 (0.3%)2 (0.1%)10 (0.5%)14 (0.3%)0.179
 Sm resistance16 (2.3%)37 (2.4%)56 (2.8%)109 (2.6%)0.761
Multidrug-resistance TB42 (100.0%)81 (100.0%)56 (100.0%)179 (100.0%) 
 Resistance to any SLIDa5 (11.9%)14 (17.3%)7 (12.5%)26 (14.5%)0.633
 Km resistance4 (9.5%)13 (16.0%)7 (12.5%)24 (13.4%)0.585
 Am resistance4 (9.5%)10 (12.3%)7 (12.5%)21 (11.7%)0.878
 Cm resistance3 (7.1%)10 (12.3%)7 (12.5%)20 (11.2%)0.638
 Sm resistance15 (35.7%)24 (29.6%)20 (35.7%)59 (33.0%)0.690
  1. Abbreviations: TB tuberculosis, SLID second-line injectable drug, Km kanamycin, Am amikacin, Cm capreomycin, Sm streptomycin
  2. aAny second-line injectable drugs refer to kanamycin, amikacin, or capreomycin